Novo Nordisk CEO on Q4 results, soaring demand for Wegovy and Ozempic

Poison centers see spike weight-loss drug calls

Novo Nordisk extends curbs on hot weight-loss drug

FDA approves Novo Nordisk’s Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

How Novo Nordisk's ‘select’ study results could shake up the obesity drug space

Novo Nordisk Diabetes Awareness Week